MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Curis Company Profile (NASDAQ:CRIS)

Consensus Ratings for Curis (NASDAQ:CRIS) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.25 (224.07% upside)

Analysts' Ratings History for Curis (NASDAQ:CRIS)
Show:
DateFirmActionRatingPrice TargetActions
6/13/2016FBR & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/3/2016Robert W. BairdReiterated RatingOutperform$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016SunTrustInitiated CoverageBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Roth CapitalReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/6/2015OppenheimerReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Curis (NASDAQ:CRIS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q116($0.08)($0.07)$2.30 million$1.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.12)($0.10)$2.98 million$2.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.08)($0.04)$2.82 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.06)($0.06)$3.50 million$2.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.06)($0.07)$2.27 million$1.17 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q4 14($0.07)($0.07)$2.69 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.04)($0.06)$4.13 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.05)($0.02)$3.46 million$4.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.06)($0.06)$1.88 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2014Q413($0.08)($0.05)$1.59 million$1.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.01)($0.02)$6.44 million$7.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2013Q2 2013($0.05)($0.02)$4.43 million$5.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2013Q1 2013($0.05)($0.06)$3.86 million$0.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/20/2013Q4 2012($0.08)($0.15)$2.07 million$1.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2012Q312($0.08)($0.04)$1.01 million$0.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.05)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2012$0.02$0.03ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.07)($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Curis (NASDAQ:CRIS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.08)($0.05)($0.07)
Q2 20164($0.10)($0.05)($0.08)
Q3 20164($0.13)($0.06)($0.10)
Q4 20164($0.12)($0.05)($0.09)
(Data provided by Zacks Investment Research)
Dividend History for Curis (NASDAQ:CRIS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Curis (NASDAQ:CRIS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/27/2016Martyn D GreenacreDirectorSell15,000$1.69$25,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Kenneth I KaitinDirectorSell15,000$1.76$26,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2015Daniel R. PasseriDirectorSell14,400$3.01$43,344.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Daniel R. PasseriDirectorSell11,200$2.91$32,592.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/28/2015Daniel R. PasseriDirectorSell13,600$2.85$38,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Daniel R. PasseriDirectorSell48,900$2.78$135,942.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2015Daniel R. PasseriDirectorSell289,000$2.99$864,110.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2014Ali Ph.D. FattaeyCEOBuy62,890$1.60$100,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Ali Ph.D. FattaeyCOOBuy3,000$2.52$7,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2013Michael GrayCFOBuy10,000$2.86$28,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2013Kenneth PientaDirectorBuy20,000$2.95$59,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013James McnabDirectorSell50,000$4.00$200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2012Daniel R PasseriCEOBuy25,000$3.03$75,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Curis (NASDAQ:CRIS)
DateHeadline
06/26/16 03:05 PMHow Many Curis, Inc. (NASDAQ:CRIS)'s Analysts Are Bullish? - Press Telegraph
06/23/16 02:16 PMNew Broker Ratings For Curis, Inc. (CRIS) - FTSE News
06/22/16 03:34 PMNotable Mover: Curis, Inc. (NASDAQ:CRIS) - iStreetWire
06/22/16 08:07 AMCuris May Make A Splash In Immune Checkpoint Inhibition - Seeking Alpha
06/22/16 08:07 AMRecently Issued Stock Ratings For Curis, Inc. (CRIS) - Fiscal Standard
06/21/16 08:08 AMCuris (CRIS) Doses First Patient in CA-170 Phase 1 as Immune Checkpoints Inhibitor
06/21/16 08:08 AMCuris Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule
06/21/16 06:09 AMCuris Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints - [at noodls] - LEXINGTON, Mass., June 21, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the ...
06/20/16 03:21 PMInvestors Watch List: The McClatchy Company (NYSE:MNI), Curis, Inc. (NASDAQ:CRIS), Ford Motor Company (NYSE:F ... - KC Register
06/10/16 10:55 AMCuris (CRIS) Announces Presentation of Updated CUDC-907 Phase 1 Data in DLBCL at EHA Meeting
06/09/16 03:22 PMCuris, Inc. (NASDAQ:CRIS) Went Up 2.16%: FMSA Holdings Inc (NYSE:FMSA), Bank of Commerce Holdings ... - KC Register
06/08/16 01:15 PMETF’s with exposure to Curis, Inc. : June 8, 2016 -
06/08/16 11:34 AMAbbVie Inc. (NYSE:ABBV) Went Up 0.45%: Curis, Inc. (NASDAQ:CRIS), Northwestern Corporation (NYSE:NWE ... - KC Register
06/08/16 06:00 AMCuris Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association - [GlobeNewswire] - LEXINGTON, Mass., June 08, 2016-- Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced ...
06/06/16 03:13 PMRevisiting My Basket Of Biotech 'Bargains' - Seeking Alpha
06/06/16 03:13 PMCURIS INC. (NASDAQ:CRIS) Financial Condition Compared to S&P 500 - CML News
06/04/16 11:40 AMCuris, Inc. (NASDAQ:CRIS) Stock Update & Estimates - Stock Tick Tock
06/04/16 11:40 AMWill Curis, Inc. (NASDAQ:CRIS) Surprise Analysts? - Investor Newswire
06/03/16 03:31 PMCuris, Inc. (CRIS) Given Outperform Rating at Robert W. Baird - Let Me Know About This
06/01/16 03:32 PMCompany Update (NASDAQ:CRIS): Curis, Inc. Announces FDA Acceptance of Investigational New Drug Application for ... - Smarter Analyst - Company Update (NASDAQ:CRIS): Curis, Inc. Announces FDA Acceptance of Investigational New Drug Application for ...Smarter AnalystCuris, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted ...Curis Says FDA Accepts Investigational New Drug Application For Anti-Cancer Drug (NASDAQ:CRIS)Sonoran Weekly Reviewall 2 news articles »
06/01/16 11:22 AMStock Review and Earnings Check on Curis, Inc. (NASDAQ:CRIS) - HNN - Stock Review and Earnings Check on Curis, Inc. (NASDAQ:CRIS)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Curis, Inc. (NASDAQ:CRIS) to ...and more »
06/01/16 06:23 AMCuris Announces FDA Acceptance of Investigational New Drug Application for CA-170, the First Orally Available Small Molecule to Target and Inhibit Immune Checkpoints - [at noodls] - LEXINGTON, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the ...
06/01/16 06:13 AMQ1 2016 Curis Inc Earnings Conference Call - [at noodls] - Q1 2016 Curis Inc Earnings Conference Call The text version of this document is not available at the moment. The original content was posted at original link . Curis Inc. published this content on 09 May ...
05/26/16 07:11 AMInvestors Checklist Stocks: VIVUS, Inc. (NASDAQ:VVUS) , Curis, Inc. (NASDAQ:CRIS) , - Street Updates - Investors Checklist Stocks: VIVUS, Inc. (NASDAQ:VVUS) , Curis, Inc. (NASDAQ:CRIS) ,Street UpdatesOn 5/25/2016, shares of VIVUS, Inc. (NASDAQ:VVUS) rose +1.63% in trading session and finally closed at $1.25. The company most recent volume stood at 727.37 thousand shares as compared to its average volume of 941.88 thousand shares. Over the one ...and more »
05/25/16 10:13 AMEarnings Review and Stock Rundown for Curis, Inc. (NASDAQ:CRIS) - Wall Street Hints and News - Earnings Review and Stock Rundown for Curis, Inc. (NASDAQ:CRIS)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Curis, Inc. (NASDAQ:CRIS) to post ...and more »
05/23/16 06:39 PMMorning Buzz: Nanosphere, Inc. (NASDAQ:NSPH), Curis, Inc. (NASDAQ:CRIS), Telefonica Brasil S.A. (NYSE:VIV ... - KC Register - Morning Buzz: Nanosphere, Inc. (NASDAQ:NSPH), Curis, Inc. (NASDAQ:CRIS), Telefonica Brasil S.A. (NYSE:VIV ...KC RegisterCuris, Inc. (NASDAQ:CRIS) traded 408883 shares and its share price advanced 1.85% to close at $1.65. Company has 0.20% insider ownership. Curis, Inc. (NASDAQ:CRIS) quarterly performance is 7.14% while its year to date (YTD) performance is -43.30%.and more »
05/23/16 06:39 PMCuris, Inc. (NASDAQ:CRIS) Impact Score At 0 - Investor Newswire - Curis, Inc. (NASDAQ:CRIS) Impact Score At 0Investor NewswireAlpha One explored various online articles released on Curis, Inc. (NASDAQ:CRIS), and it set a daily sentiment score of 0.31 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content issued on ...and more »
05/23/16 11:48 AMStock Rating Review for Curis, Inc. (NASDAQ:CRIS) - Wall Street Hints and News - Stock Rating Review for Curis, Inc. (NASDAQ:CRIS)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Curis, Inc. (NASDAQ:CRIS). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is compiled by ...and more »
05/22/16 06:03 PMAre Analysts Bullish Curis, Inc. (NASDAQ:CRIS) After Last Week? - Wall Street Hints and News - Are Analysts Bullish Curis, Inc. (NASDAQ:CRIS) After Last Week?Wall Street Hints and NewsOut of 4 analysts covering Curis (NASDAQ:CRIS), 0 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Curis has been the topic of 6 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Below is a list of Curis ...
05/20/16 03:03 PMCURIS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/19/16 06:12 PMETF’s with exposure to Curis, Inc. : May 19, 2016 -
05/17/16 01:22 PMCuris, Inc. :CRIS-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 10:44 AMCuris, Inc.: Low-Priced Radar Dodger Or Blood Cancer Bust? - Seeking Alpha - Curis, Inc.: Low-Priced Radar Dodger Or Blood Cancer Bust?Seeking AlphaCuris, Inc. (NASDAQ:CRIS) is one such biotech developing a novel drug for an aggressive form of lymphoma. Today, we'll take a look at it from the financial and scientific perspectives, and I'll give my opinion on the risks and potential rewards of this ...
05/16/16 06:20 PMAlpha One Assigns Impact Score Of 100 To Curis, Inc. (NASDAQ:CRIS) - Investor Newswire - Alpha One Assigns Impact Score Of 100 To Curis, Inc. (NASDAQ:CRIS)Investor NewswireAlpha One analyzed the various web articles published on Curis, Inc. (NASDAQ:CRIS), and thereafter it gave company a daily sentiment score of 0.31. The entity designs algorithm based assessment to known stock sentiment on stock after considering the ...and more »
05/16/16 11:58 AMPrice Target by Brokers: Curis, Inc. (NASDAQ:CRIS) - News Oracle - Price Target by Brokers: Curis, Inc. (NASDAQ:CRIS)News OracleLast Trade: The Company fell -4.55% and finished at $1.68. The daily volume was measured at 1.07 million shares. The 52-week high of the share price is $3.75 and the 52-week low is $1.25. The company has a market cap of $207.16 million. Its latest ...and more »
05/13/16 06:55 PMCuris, Inc. (CRIS) Updated Broker Price Targets - Share Trading News - Curis, Inc. (CRIS) Updated Broker Price TargetsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Curis, Inc. (CRIS). The latest reports which are currently in issue on Thursday 12th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts ...and more »
05/11/16 07:04 PMFBR & Co. Reaffirms Buy Rating for Curis, Inc. (CRIS) - Washington News Wire - Washington News WireFBR & Co. Reaffirms Buy Rating for Curis, Inc. (CRIS)Washington News WireCuris, Inc. (NASDAQ:CRIS)'s stock had its “buy” rating reissued by equities researchers at FBR & Co. in a research report issued to clients and investors on Tuesday, MarketBeat.Com reports. Curis (NASDAQ:CRIS) opened at 1.92 on Tuesday. The company's ...Curis' (CRIS) Buy Rating Reaffirmed at FBR & Co.Web Breaking NewsCuris Inc Receives a Buy from FBR CapitalMarkets.coall 3 news articles »
05/11/16 07:04 PMFY2016 Earnings Estimate for Curis, Inc. (CRIS) Issued By SunTrust - Washington News Wire - Washington News WireFY2016 Earnings Estimate for Curis, Inc. (CRIS) Issued By SunTrustWashington News WireCuris logo Curis, Inc. (NASDAQ:CRIS) – SunTrust decreased their FY2016 earnings per share estimates for Curis in a report released on Monday, Zacks Investment Research reports. SunTrust analyst P. Lawson now anticipates that the brokerage will post ...
05/10/16 05:07 AMPerformance Recap and Target Perspective on Curis, Inc. (NASDAQ:CRIS) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Curis, Inc. (NASDAQ:CRIS)B.O.D.Y ConfidentialIn the latest trading session, shares of Curis, Inc. (NASDAQ:CRIS) moved +3.91%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, company shares ...and more »
05/10/16 05:07 AMStock Update (NASDAQ:CRIS): Curis, Inc. Reports First Quarter 2016 Financial Results - Smarter Analyst - NewsWay 21Stock Update (NASDAQ:CRIS): Curis, Inc. Reports First Quarter 2016 Financial ResultsSmarter AnalystCRIS2 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, reported its financial results for the first quarter ended March ...Curis, Inc. (CRIS) Now Covered by Cowen and CompanyNewsWay 21Curis, Inc. (CRIS) Announces Quarterly Earnings ResultsWeb Breaking NewsNext Weeks Broker Price Targets For Curis, Inc. (CRIS)Share Trading NewsRisers & Fallers -B.O.D.Y Confidential -Sonoran Weekly Reviewall 11 news articles »
05/09/16 06:47 PMCheck on Analyst Ratings Curis, Inc. (NASDAQ:CRIS) - B.O.D.Y Confidential - Check on Analyst Ratings Curis, Inc. (NASDAQ:CRIS)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1 on shares of Curis, Inc. (NASDAQ:CRIS). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale. A 1 or 2 ...and more »
05/09/16 06:47 PMCuris, Inc. (NASDAQ:CRIS) Latest Impact Score At 70 - Investor Newswire - Curis, Inc. (NASDAQ:CRIS) Latest Impact Score At 70Investor NewswireCuris, Inc. (NASDAQ:CRIS) has a 0.305 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published on different online ...and more »
05/09/16 01:34 PMEdited Transcript of CRIS earnings conference call or presentation 9-May-16 12:30pm GMT -
05/09/16 07:43 AMCuris reports 1Q loss -
05/09/16 07:30 AMCuris Inc Earnings Call scheduled for 8:30 am ET today -
05/09/16 07:18 AMCuris Reports First Quarter 2016 Financial Results - [at noodls] - LEXINGTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the ...
05/09/16 07:18 AMView all press releases » - [at noodls] - Date Title and Summary View May 9, 2016 LEXINGTON, Mass., May 09, 2016 (GLOBE NEWSWIRE) --... This is an abstract of the original noodl. To continue reading this document, click here for the original version....
05/09/16 07:03 AM8:03 am Curis beats by $0.01, misses on revs -
05/09/16 07:02 AMCURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -
05/09/16 06:07 AMQ1 2016 Curis Inc Earnings Release - Before Market Open -
About Curis

Curis logoCuris, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CRIS
  • CUSIP: 23126910
Key Metrics:
  • Previous Close: $1.66
  • 50 Day Moving Average: $1.73
  • 200 Day Moving Average: $1.88
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $209.27M
  • Current Quarter EPS Consensus Estimate: $-0.36 EPS
Additional Links:
Curis (NASDAQ:CRIS) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha